WE ARE CURRENTLY HIRING A REGIONAL MANAGER FOR ASEAN - DETAILS HERE
ORIGINAL RESEARCH
We work with scientists and international policy experts to develop white papers, briefings and other resources, so that parliamentarians and their supporters have the information they need to drive meaningful, evidence-based change.
DRIVING INCREASED FUNDING FOR TB THROUGH PARLIAMENTARY BUDGET ACTION
Today, the single biggest factor that hampers the TB response and our ability to get back on track is the lack of funding. Parliaments have formal, often constitutional, roles in shaping, approving and monitoring national budgets.
Informed by a budget mapping exercise across 22 priority countries and in-depth interviews with parliamentarians, advocates and experts across the Americas, Africa, and Asia-Pacific, this report summarises best practice recommendations for engaging in parliamentary budget processes.
The report can be downloaded here.
THE PRICE OF A PANDEMIC
The Global TB Caucus commissioned KPMG to research the possible cost of TB to the global economy.
Download the research here.
THE ECONOMIC IMPACT OF TB MORTALITY IN 120 COUNTRIES
Adapted especially for the Global TB Caucus from the work of Sachin Silva, Michael Reid, and Ambassador Eric Goosby, this briefing studies the economic impact of TB in the light of three different scenarios where we meet the End TB Targets in 2030, 2045, or keep going at the current rate of progress.
The briefing can be downloaded here.
THE PRICE OF A PANDEMIC BRIEFING ON THE G20'S BIGGEST INFECTIOUS KILLER
Using data drawn from the UK government's independent Review of Antimicrobial Resistance (AMR) in 2016, GTBC produced this report outlining the causes and predicted impact of TB and multi-drug resistant TB in the G20.
The briefing can be downloaded here.
LEGISLATIVE RESOURCES
We have also developed a number of bespoke resources focused on legislation to help our members drive progress through their parliaments.
FROM OUR PARTNERS
The Global TB Caucus is global network of parliamentarians uniting across borders and ideologies to drive political action, change policies, and secure funding. We can't do that work without close collaboration with a wide range of domestic, regional, and global partners - especially civil society organisations in high TB burden countries.
Below you will find publications from our partners that we think are particularly valuable for our work.
STOP TB PARTNERSHIP
THE GLOBAL PLAN TO END TB
The Global Plan to End TB, 2023-2030 is a plan for ending TB as a public health challenge by 2030. It provides a blueprint of priority actions required and a detailed estimate of financial resources needed to end TB. This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implementing TB care and prevention and R&D into new tools. This Global Plan has already informed the Global Fund Investment Case and the 2022 G20 deliberations on TB. It will serve as a key document for inspiring and aligning global advocacy efforts, such as for the upcoming UNHLM on TB in 2023.
THE GLOBAL FUND
INVESTMENT CASE FOR THE 8th REPLENISHMENT
The Global Fund partnership has made remarkable progress in the fight against HIV, tuberculosis (TB) and malaria over the last two decades – saving 65 million lives and reducing the combined death rate from AIDS, TB and malaria by 63% since 2002.
But interconnected crises threaten those hard-won gains. If we don’t respond with the urgency that this moment demands, we risk reversing these lifesaving achievements. For our Eighth Replenishment, the Global Fund needs US$18 billion to save 23 million lives between 2027 and 2029, reduce the combined mortality rate by another 64%, relative to 2023 levels, and prevent around 400 million infections.
TREATMENT ACTION GROUP (TAG)
PIPELINE REPORT - VACCINES 2024
The report provides the latest information on 17 vaccine candidates under clinical development and summarises ongoing, planned, and recently completed clinical trials in two comprehensive tables.
The world will not end the TB epidemic without new vaccines. Decades of investment in TB research and development are starting to bear fruit with multiple vaccine candidates in late-stage efficacy trials. Although the field has reason for well-earned optimism, progress is tenuous. Frick presents promising developments in the pipeline considering these new realities and what they may mean for TB vaccine science.
